Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Eli Lilly & Co. The associated price target remains the same with $1,200.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evan Seigerman has given his Buy rating due to a combination of factors that underscore Eli Lilly’s strengthening competitive position and long-term growth outlook. He sees the company consolidating its leadership in obesity treatments as access to incretin therapies broadens in the U.S. and internationally, supported by expanding reimbursement, growing use of Lilly’s direct-to-patient platform, and improved commercial coverage. He also highlights that management expects solid earnings expansion, with revenue growth driven primarily by higher volumes in the incretin franchise and operating leverage coming from slower SG&A growth relative to sales, even as R&D remains robust. In addition, the resolution of the Section 232 investigation removes a key overhang, reducing regulatory uncertainty around the business.
Seigerman further points to the significant market opportunity for orforglipron, anticipated to launch around mid‑2026, which is positioned as a flexible oral option for induction, maintenance, and for markets where injectable therapies are harder to deploy. He notes that Lilly has a clear and well-resourced strategy to defend and extend its leadership in an increasingly crowded obesity market, anchored by a broad incretin portfolio and industry-leading manufacturing capacity. Beyond obesity, he emphasizes the diversification benefits from Lilly’s presence in other therapeutic areas such as Lp(a) and Alzheimer’s disease, where the donanemab approval validates the company’s R&D strategy. Taken together, these factors underpin his view that Eli Lilly’s top-line and bottom-line growth should outpace peers and consensus, justifying a Buy recommendation.
In another report released yesterday, TipRanks – Anthropic also reiterated a Buy rating on the stock with a $1,199.00 price target.